Overview

LIPS-A: Lung Injury Prevention Study With Aspirin

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The primary hypothesis was that early aspirin administration will decrease the rate of developing acute lung injury during the first 7 days after presentation to the hospital.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Beth Israel Deaconess Medical Center
Montefiore Medical Center
National Center for Research Resources (NCRR)
National Heart, Lung, and Blood Institute (NHLBI)
Vanderbilt University
Vanderbilt University Medical Center
Treatments:
Aspirin